Beta-blockers in critical care and obstructive lung diseases

New directions

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Beta-adrenergic blocking agents (i.e., β-blockers) are extensively used for myriad conditions, though their use in patients with critical illness is controversial. Concerns over their negative chronotropic, anti-hypertensive, and potential bronchospastic effects temper their use in sepsis, especially in patients with underlying obstructive lung diseases. Beta-blockers are commonly used in critically-ill patients with atrial arrhythmias, particularly atrial fibrillation, though guidelines supporting their use in such patients are lacking. Similarly, guidelines for β-blockers to combat the stimulant effects of sympathomimetic drugs such as amphetamines and cocaine are mainly based on expert opinion, and controversy exists as to which β-blocking agents are superior. This chapter will focus on the data surrounding the use of β-blockers in common illnesses seen in the intensive care unit and their effects on obstructive lung diseases.

Original languageEnglish (US)
Title of host publicationBeta-Blockers
Subtitle of host publicationPhysiological, Pharmacological and Therapeutic Implications
PublisherNova Science Publishers, Inc.
Pages79-106
Number of pages28
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

Fingerprint

Obstructive Lung Diseases
Critical Care
Critical Illness
Guidelines
Amphetamines
Sympathomimetics
Adrenergic beta-Antagonists
Expert Testimony
Cocaine
Atrial Fibrillation
Antihypertensive Agents
Intensive Care Units
Cardiac Arrhythmias
Sepsis
Direction compound

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kuhn, B., Stewart, E. P., Avdalovic, M. V., Albertson, T. E., & Schivo, M. (2018). Beta-blockers in critical care and obstructive lung diseases: New directions. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications (pp. 79-106). Nova Science Publishers, Inc..

Beta-blockers in critical care and obstructive lung diseases : New directions. / Kuhn, Brooks; Stewart, E. Pierce; Avdalovic, Mark V; Albertson, Timothy E; Schivo, Michael.

Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. p. 79-106.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kuhn, B, Stewart, EP, Avdalovic, MV, Albertson, TE & Schivo, M 2018, Beta-blockers in critical care and obstructive lung diseases: New directions. in Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., pp. 79-106.
Kuhn B, Stewart EP, Avdalovic MV, Albertson TE, Schivo M. Beta-blockers in critical care and obstructive lung diseases: New directions. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc. 2018. p. 79-106
Kuhn, Brooks ; Stewart, E. Pierce ; Avdalovic, Mark V ; Albertson, Timothy E ; Schivo, Michael. / Beta-blockers in critical care and obstructive lung diseases : New directions. Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. pp. 79-106
@inbook{cc181fe492a24833be8919f75febb99d,
title = "Beta-blockers in critical care and obstructive lung diseases: New directions",
abstract = "Beta-adrenergic blocking agents (i.e., β-blockers) are extensively used for myriad conditions, though their use in patients with critical illness is controversial. Concerns over their negative chronotropic, anti-hypertensive, and potential bronchospastic effects temper their use in sepsis, especially in patients with underlying obstructive lung diseases. Beta-blockers are commonly used in critically-ill patients with atrial arrhythmias, particularly atrial fibrillation, though guidelines supporting their use in such patients are lacking. Similarly, guidelines for β-blockers to combat the stimulant effects of sympathomimetic drugs such as amphetamines and cocaine are mainly based on expert opinion, and controversy exists as to which β-blocking agents are superior. This chapter will focus on the data surrounding the use of β-blockers in common illnesses seen in the intensive care unit and their effects on obstructive lung diseases.",
author = "Brooks Kuhn and Stewart, {E. Pierce} and Avdalovic, {Mark V} and Albertson, {Timothy E} and Michael Schivo",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536133110",
pages = "79--106",
booktitle = "Beta-Blockers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Beta-blockers in critical care and obstructive lung diseases

T2 - New directions

AU - Kuhn, Brooks

AU - Stewart, E. Pierce

AU - Avdalovic, Mark V

AU - Albertson, Timothy E

AU - Schivo, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Beta-adrenergic blocking agents (i.e., β-blockers) are extensively used for myriad conditions, though their use in patients with critical illness is controversial. Concerns over their negative chronotropic, anti-hypertensive, and potential bronchospastic effects temper their use in sepsis, especially in patients with underlying obstructive lung diseases. Beta-blockers are commonly used in critically-ill patients with atrial arrhythmias, particularly atrial fibrillation, though guidelines supporting their use in such patients are lacking. Similarly, guidelines for β-blockers to combat the stimulant effects of sympathomimetic drugs such as amphetamines and cocaine are mainly based on expert opinion, and controversy exists as to which β-blocking agents are superior. This chapter will focus on the data surrounding the use of β-blockers in common illnesses seen in the intensive care unit and their effects on obstructive lung diseases.

AB - Beta-adrenergic blocking agents (i.e., β-blockers) are extensively used for myriad conditions, though their use in patients with critical illness is controversial. Concerns over their negative chronotropic, anti-hypertensive, and potential bronchospastic effects temper their use in sepsis, especially in patients with underlying obstructive lung diseases. Beta-blockers are commonly used in critically-ill patients with atrial arrhythmias, particularly atrial fibrillation, though guidelines supporting their use in such patients are lacking. Similarly, guidelines for β-blockers to combat the stimulant effects of sympathomimetic drugs such as amphetamines and cocaine are mainly based on expert opinion, and controversy exists as to which β-blocking agents are superior. This chapter will focus on the data surrounding the use of β-blockers in common illnesses seen in the intensive care unit and their effects on obstructive lung diseases.

UR - http://www.scopus.com/inward/record.url?scp=85048385195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048385195&partnerID=8YFLogxK

M3 - Chapter

SN - 9781536133110

SP - 79

EP - 106

BT - Beta-Blockers

PB - Nova Science Publishers, Inc.

ER -